⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1087661 | 1.00 | — | — | |
| SCHEMBL1087663 | 1.00 | — | — | |
| SCHEMBL10074744 | 0.72 | — | — | |
| SCHEMBL10577901 | 0.72 | — | — | |
| SCHEMBL10077537 | 0.70 | — | — | |
| SCHEMBL1104439 | 0.70 | — | — | |
| SCHEMBL11487721 | 0.67 | — | — | |
| SCHEMBL16639156 | 0.67 | — | — | |
| SCHEMBL5426437 | 0.65 | NLRP3 (0.39) | — | |
| SCHEMBL10948785 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354546-B2 | Process for manufacture of optically active 2-(acyloxymethyl)-1,3-oxathiolanes | Vertichem Corporation (CA) | 2013-01-15 | — | — | US | claimed |
| US-20120157693-A1 | Process for Manufacture of Optically Active 2-(Acyloxymethyl)-1,3-Oxathiolanes | THESIS CHEMISTRY, LLC (US) | 2012-06-21 | — | — | US | claimed |
| US-8153416-B2 | Process for manufacture of optically active 2-(acyloxymethyl)-1,3-oxathiolanes using enzymatic resolution | THESIS CHEMISTRY, LLC (US) | 2012-04-10 | — | — | US | claimed |
| WO-2010068756-A2 | PROCESS FOR MANUFACTURE OF OPTICALLY ACTIVE 2-(ACYLOXYMETHYL)-1, 3 OXATHIOLANES | THESIS CHEMISTRY, LLC (US) | 2010-06-17 | — | — | WO | claimed |
| US-20100143978-A1 | Process for Manufacture of Optically Active 2-(Acyloxymethyl)-1,3-Oxathiolanes | THESIS CHEMISTRY, LLC (US) | 2010-06-10 | — | — | US | claimed |
| US-20260071249-A1 | PRODUCTS FOR REGULATION OF EUKARYOTIC AND MICROBIAL CELLS GROWTH | TETS VICTOR (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260071247-A1 | PRODUCTS FOR REGULATION OF EUKARYOTIC AND MICROBIAL CELLS GROWTH | TETS VICTOR (US) | 2026-03-12 | — | — | US | disclosed |
| US-20240182945-A1 | PRODUCTS FOR REGULATION OF EUKARYOTIC AND MICROBIAL CELLS GROWTH | TETS VICTOR (US) | 2024-06-06 | — | — | US | disclosed |
| EP-4017503-A1 | DDX17 AND NLRC4 TARGETING FOR INFLAMMATORY DISEASES | University of Virginia Patent Foundation (US) | 2022-06-29 | — | — | EP | disclosed |
| WO-2021076197-A1 | CONJUGATE MOLECULES | DIVERSE BIOTECH, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2020263888-A1 | CANNABINOID CONJUGATE MOLECULES | DIVERSE BIOTECH, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| US-8354546-B2 | Process for manufacture of optically active 2-(acyloxymethyl)-1,3-oxathiolanes | Vertichem Corporation (CA) | 2013-01-15 | — | — | US | disclosed |
| EP-1473294-B1 | Substituted 1,3-oxathiolanes with antiviral properties | SHIRE BIOCHEM INC (CA) | 2007-04-18 | — | — | EP | disclosed |
| EP-1473294-A2 | Substituted 1,3-oxathiolanes with antiviral properties | Shire Biochem Inc. (CA) | 2004-11-03 | — | — | EP | disclosed |
| EP-1153924-B1 | Substituted 1,3-oxathiolanes with antiviral properties | SHIRE BIOCHEM INC (CA) | 2004-09-01 | — | — | EP | disclosed |
| US-6369066-B1 | HIV INFECTIONS | BIOCHEM PHARMA, INC. (CA) | 2002-04-09 | — | — | US | disclosed |
| EP-0756595-B1 | SUBSTITUTED 1,3-OXATHIOLANES WITH ANTIVIRAL PROPERTIES | SHIRE BIOCHEM INC (CA) | 2002-03-06 | — | — | EP | disclosed |
| EP-1153924-A2 | Substituted 1,3-oxathiolanes with antiviral properties | BIOCHEM PHARMA INC (CA) | 2001-11-14 | — | — | EP | disclosed |
| US-6228860-B1 | ADMINISTERING TO TREAT HUMAN IMMUNODEFICIENCY OR HEPATITIS VIRUS INFECTIONS IN MAMMALS RESISTANT TO 3TC OR FTC | BIOCHEM PHARMA INC. (CA) | 2001-05-08 | — | — | US | disclosed |
| US-5587480-A | TREATING HIV AND HEPATITIS VIRUS INFECTIONS | BIOCHEM PHARMA, INC. (CA) | 1996-12-24 | — | — | US | disclosed |